Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aung Naing

Showing results (1-10 of 397) with videos related to

Pageof 40
Sort By:
Expert Opinion on Investigational Drugs|May 2, 2013
Overcoming resistance to mTOR inhibition for enhanced strategies in clinical trialsAung Naing
The Lancet. Oncology|August 14, 2019
A new screening tool for FGFR inhibitor treatment?Aung Naing
Cancer Chemotherapy and Pharmacology|February 28, 2013
Dodging a dogma: is treating beyond progression beneficial?Aung Naing, Razelle Kurzrock
Clinical Colorectal Cancer|April 10, 2010
Chemotherapy resistance and retreatment: a dogma revisitedAung Naing, Razelle Kurzrock
Trends in Cancer|June 15, 2023
Interleukin-10 in cancer immunotherapy: from bench to bedsideMohamad Adham Salkeni, Aung Naing
American Journal of Hematology|September 3, 2005
Methotrexate-induced status epilepticusAung Naing, Don Luong, Martine Extermann
Oncology|December 17, 2013
TAS-106: preclinical, clinical and beyondMaen Abdelrahim, Akira Matsuda, Aung Naing
The American Journal of Medicine|January 28, 2010
Juice plus or toxicity plusAung Naing, Joann Aaron, Razelle Kurzrock
Expert Opinion on Investigational Drugs|August 28, 2013
Metformin: an old drug with new potentialJoud Hajjar, Mouhammed Amir Habra, Aung Naing
Journal for Immunotherapy of Cancer|November 2, 2021
Letter to the editor from Pant <i>et al</i>Shubham Pant, Justin T Moyers, Aung Naing
Pageof 40

Showing results (1-10 of 397) with videos related to

Sort By:
Pageof 40
Expert Opinion on Investigational Drugs|May 2, 2013
Overcoming resistance to mTOR inhibition for enhanced strategies in clinical trialsAung Naing
The Lancet. Oncology|August 14, 2019
A new screening tool for FGFR inhibitor treatment?Aung Naing
Cancer Chemotherapy and Pharmacology|February 28, 2013
Dodging a dogma: is treating beyond progression beneficial?Aung Naing, Razelle Kurzrock
Clinical Colorectal Cancer|April 10, 2010
Chemotherapy resistance and retreatment: a dogma revisitedAung Naing, Razelle Kurzrock
Trends in Cancer|June 15, 2023
Interleukin-10 in cancer immunotherapy: from bench to bedsideMohamad Adham Salkeni, Aung Naing
American Journal of Hematology|September 3, 2005
Methotrexate-induced status epilepticusAung Naing, Don Luong, Martine Extermann
Oncology|December 17, 2013
TAS-106: preclinical, clinical and beyondMaen Abdelrahim, Akira Matsuda, Aung Naing
The American Journal of Medicine|January 28, 2010
Juice plus or toxicity plusAung Naing, Joann Aaron, Razelle Kurzrock
Expert Opinion on Investigational Drugs|August 28, 2013
Metformin: an old drug with new potentialJoud Hajjar, Mouhammed Amir Habra, Aung Naing
Journal for Immunotherapy of Cancer|November 2, 2021
Letter to the editor from Pant <i>et al</i>Shubham Pant, Justin T Moyers, Aung Naing
Pageof 40